On November 19, 2025, Agios reported topline results from its RISE UP Phase 3 trial of Mitapivat in Sickle Cell Disease. While the trial met one of its primary endpoints, it failed to achieve in the other, falling shy of a statistically significant improvement in annualized rate of pain (“pain crises”). Additionally, the “key secondary endpoint of change from baseline in PROMIS Fatigue was not met.”
Following this news, Agios’ stock price fell by $22.33 per share to open at $23.16 per share.
To receive more information, please fill out the form.
